BioSpace News Archive

60 Degrees Pharmaceuticals Inc. (“60P” or the “Company”) (Nasdaq: SXTP), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced that the Canadian Intellectual Property Office (CIPO) has issued the Company a patent covering the use of novel regimens of tafenoquine for the prevention of malaria in malaria-naive individuals.

Neurona Therapeutics today announced the appointment of James Stutz, a business and finance executive with over 20 years of experience in the biopharma industry, as chief financial officer (CFO) and chief business officer (CBO).

Crinetics Pharmaceuticals, Inc. announced that it will host a Key Opinion Leader webinar on August 8, 2023 at 12:00 pm Eastern Time, featuring presentations by KOLs Beverly MK Biller M.D. and Karen JP Liebert, R.N., BSN, both of Massachusetts General Hospital, who will discuss the current landscape and unmet medical need in acromegaly, as well as the treatment burden associated with standard-of-care injectable somatostatin receptor ligands.

Daré Bioscience, Inc. today announced it was awarded a grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) of the National Institutes of Health (NIH) in the amount of approximately $385,000 to support activities related to the conduct and completion of proof-of-concept target validation studies in support of a potential new approach for the prevention and treatment of idiopathic preterm birth.

Checkpoint Therapeutics, Inc. today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 3,236,248 shares of its common stock (or pre-funded warrants in lieu thereof), Series A warrants to purchase up to 3,236,248 shares of common stock.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, provides an update on the ongoing development of its product candidates, eftilagimod alpha (efti) and IMP761 for its fiscal fourth quarter ended 30 June 2023 (Q4 FY23).

Recce Pharmaceuticals Ltd today announced a poster presentation on in vitro, in vivo, and clinical data of its lead synthetic anti-infective, RECCE ® 327, at the 2023 Military Health System Research Symposium (MHSRS) taking place August 14-17, 2023 at the Gaylord Palms Resort & Convention Center in Kissimmee, Florida.

DIANT® Pharma Inc. is excited to announce the US Food and Drug Administration’s recent acquisition of the DIANT® LiFT system.

AUSTRALIAN cancer patients who have been diagnosed with rare soft tissue sarcomas will now have affordable access to a global therapy shown to improve survival, following its listing on the Pharmaceutical Benefits Scheme.

Opteev Technologies, Inc., a pioneering technology company at the forefront of diagnostics, has filed a patent for a revolutionary multiplex biochip for respiratory infection diagnostics.